MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)

Firas El Chaer,Lindsay Rein,Kazuya Shimoda,Junichiro Yuda,Tamanna Haque,James Mccloskey,Akiyoshi Takami,Masafumi Fukaya,Shuichi Shirane,Sujan Kabir,Jian Mei,Masataka Seki,Zhonggai Li,Mark Wade,Claudia Lebedinsky,Raajit K Rampal

doi:10.1016/s2152-2650(23)01244-2

MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)

Firas El Chaer, Lindsay Rein + Show 14 more

Open Access

PDF Available

https://doi.org/10.1016/s2152-2650(23)01244-2

Copy DOI

Export

Save

Cite

Journal: Clinical Lymphoma Myeloma and Leukemia

Publication Date: Aug 31, 2023

Affiliation: University of Miyazaki, National Cancer Center Hospital East, Aichi Medical University Hospital, Juntendo University

#Myelofibrosis #Clinical Responses #Selective Kinase Inhibitor #Selective Kinase #Selective Inhibitor #PIM1 Kinase Inhibitor #Selective PIM1 #PIM1 Kinase #Preliminary Data #Kinase Inhibitor

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)